Low-dose whole-body scan as first imaging after stroke or mini-stroke
Compares a low-dose whole-body scan first against usual imaging in adults with stroke or TIA.
Plain-language title generated from the registry record
Registry title: Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA
Key facts
- Where
- Montpellier and Nîmes, FranceSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 89 years old?
Source: NCT02662751, who can take part
Where in France
- CHRU de Montpellier, Hopital Gui de ChauliacMontpellier, FranceTaking people
- CHRU de Nîmes - Hôpital Universitaire CarémeauNîmes, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Nīmes
- Trial code
- NCT02662751
- Record updated
- 10 March 2025
- Original description
The main objective of this study is to compare two post-stroke/TIA (transient ischemic attack) imaging strategies in terms of the number of clinically important (i.e. requiring specific treatment according to current recommendations) lesions detected. The first strategy is the current/usual strategy in each participating centre and the second strategy consists in starting the post-stroke/TIA imaging assessment by a whole-body, low-dose angiography and subsequently resorting to elements of the usual strategy if required.Read full original descriptionShow less
The Impact of Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke or Transient Ischemic Attack in Comparison With Usual Care: a Randomized, Controlled, Open Trial
The main objective of this study is to compare two post-stroke/TIA (transient ischemic attack) imaging strategies in terms of the number of clinically important (i.e. requiring specific treatment according to current recommendations) lesions detected. The first strategy is the current/usual strategy in each participating centre and the second strategy consists in starting the post-stroke/TIA imaging assessment by a whole-body, low-dose angiography and subsequently resorting to elements of the usual strategy if required.
Inclusion: The patient was informed about the implementation of the study, its objectives, constraints and patient rights; The patient has given free and informed consent and signed the consent; Patient affiliated with or beneficiary of a health insurance plan; Patient available for 36 months of follow-up; The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the past 10 days, ABCD2 score greater than 3) without haemorrhage.
Exclusion: The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study; The patient has already undergone a full body scanner in the previous three months; Known allergy to contrast medium or severe allergy to iodine; Known active malignancy or history of cancer treatment; History of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia); Renal failure with creatinine clearance below 60 ml / min; Patient under guardianship or judicial protection; Refusal to sign the consent; Inability to correctly inform the patient or his/her trusted person about the study; The patient is pregnant, parturient, or breastfeeding; The patient has a contraindication for a treatment used in this study; Monoclonal immunoglobulin; Emergency situations that hamper the planned course of the study.